论文部分内容阅读
目的探讨复发/难治性急性淋巴细胞白血病(ALL)患者多药耐药基因(mdr1基因)的表达及其临床意义。方法采用Northern blot法检测K562/A02细胞株mdr1基因的表达,RT-PCR法检测42例ALL患者(ALL组)、27例非白血病患者和健康人(对照组)mdr1基因的表达水平,分析mdr1基因过度表达的临床意义。结果ALL组mdr1基因过度表达率显著高于对照组(P<0.01),其中复发/难治者高于初诊和完全缓解(CR)者(P<0.01),临床耐药者高于非临床耐药者(P<0.01);非临床耐药者CR率显著高于临床耐药者(P<0.001)。结论mdr1基因过度表达与ALL患者临床耐药密切相关,是影响预后的重要因素;mdr1基因表达可作为判断ALL患者临床耐药和预后的指标。
Objective To investigate the expression of multidrug resistance gene (mdr1) in patients with relapsed / refractory acute lymphoblastic leukemia (ALL) and its clinical significance. Methods The expression of mdr1 gene in K562 / A02 cell line was detected by Northern blot. The expression of mdr1 gene was detected by RT-PCR in 42 ALL patients (ALL group), 27 non-leukemia patients and healthy controls (control group) Clinical Significance of Overexpression of Genes. Results The overexpression rate of mdr1 gene in ALL group was significantly higher than that in control group (P <0.01), and the recurrence / refractory rate in ALL group was significantly higher than that in first diagnosis and complete remission (P <0.01) (P <0.01). The CR rate in non-clinical drug-resistant group was significantly higher than that in clinical drug-resistant group (P <0.001). Conclusion The overexpression of mdr1 gene is closely related to clinical drug resistance in ALL patients and is an important factor affecting prognosis. The expression of mdr1 gene may be used as an indicator of clinical drug resistance and prognosis in patients with ALL.